1. Plasma alpha-synuclein detected by single molecule array is increased in PD
- Author
-
Fiona Setiawan, Nicole Shuang-Yu Chia, Kumar M. Prakash, Kay Yaw Tay, Adeline S.L. Ng, Samuel Yong-Ern Ng, Wing Lok Au, Zheyu Xu, Yi Jayne Tan, Louis C.S. Tan, Zhonghao Lu, Ebonne Yulin Ng, and Eng-King Tan
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,HIV Infections ,Brief Communication ,Age and gender ,Cellular and Molecular Neuroscience ,03 medical and health sciences ,chemistry.chemical_compound ,Plasma ,0302 clinical medicine ,Internal medicine ,Medicine ,Humans ,Aged ,Alpha-synuclein ,business.industry ,General Neuroscience ,Parkinson Disease ,Middle Aged ,Single Molecule Imaging ,030104 developmental biology ,Endocrinology ,chemistry ,Cancer research ,alpha-Synuclein ,Biological Assay ,Female ,Neurology (clinical) ,Brief Communications ,business ,Biomarkers ,030217 neurology & neurosurgery - Abstract
We utilized ultrasensitive single molecule technology to measure plasma alpha‐synuclein in 221 subjects (51 controls, 170 PD). Plasma alpha‐synuclein levels were significantly higher in PD than controls (15506.3 vs. 13057.0 pg/mL, P = 0.037), adjusting for age and gender. In PD, alpha‐synuclein levels did not vary by H&Y stage or UPDRS motor scores but were significantly higher in PD patients with poorer cognition (MMSE ≤ 25) than controls (P = 0.016, Bonferroni corrected P = 0.047). Alpha‐synuclein levels quantified using ultrasensitive single molecule technology discriminate PD from controls and correlate with cognitive severity. These preliminary findings require independent validation to determine the utility of this assay.
- Published
- 2018